Status: Not yet recruiting
A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors
This study is a prospective, observational, real-world, multi-center study planning to enroll 90 patients. The study will observe and document patients' actual clinical practices in receiving Iparomlimab and Tuvonralimab Injection (QL1706). The primary objectives are to evaluate the safety and effectiveness of Iparomlimab and Tuvonralimab Injection (QL1706) in treating locally advanced or metastatic solid tumors.
Participants needed: 90
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: PENG YUANUpdated: Jul 2, 2025Locations: 1Duration: 2 Years
Eligibility criteria
1) Histologically or cytologically confirmed locally advanced or metastatic soli... [+5]
1) Tumor-Related Conditions [+17]